NAYA Biosciences
NAYA Biosciences is a publicly traded clinical-stage biopharmaceutical company developing Astatine-211 targeted alpha radiopharmaceuticals and FLEX-NK bifunctional antibodies for cancers refractory to standard-of-care, with an initial focus on hepatocellular carcinoma and multiple myeloma.
- Company typePublic
- Founded2023
- HeadquartersSarasota, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What NAYA Biosciences does
NAYA Biosciences is a clinical-stage biopharmaceutical platform operating primarily through its subsidiary NAYA Therapeutics, focused on developing next-generation cancer immunotherapies for indications with limited response to current standard-of-care treatment. The company's initial focus areas are hepatocellular carcinoma (HCC) and multiple myeloma. It pursues two core technology platforms: Astatine-211 (²¹¹At) targeted alpha therapies, a radiopharmaceutical approach using a rare alpha-emitting radioisotope positioned as "the cleanest of all alpha emitters" for precise tumor-targeted radiation with minimal collateral damage, and FLEX-NK bifunctional antibodies that engage natural killer cells to attack cancer cells. The company is also building a decentralized supply chain for on-demand ²¹¹At availability, addressing the isotope's short half-life (~7.2 hours) through partnerships with Atley Solutions, Alpha Nuclide, and Ionetix, and a clinical relationship with Miami Cancer Institute.
The company makes money, in principle, through development milestones, licensing agreements, and the eventual commercialization of its cancer therapy pipelines, but as a clinical-stage entity it has not yet generated commercial revenue and no pricing or licensing economics are publicly disclosed. Its go-to-market model targets pharmaceutical partners, research institutions, and healthcare providers for licensing deals, co-development partnerships, and clinical collaborations. Marketing is conducted primarily through digital channels (LinkedIn, YouTube-hosted Astatine-211 webinar series, Access Newswire press releases) rather than a traditional sales force, consistent with a pre-commercial biotech. Customer segments are framed as oncology patients (HCC and multiple myeloma, especially those refractory to standard-of-care) and pharmaceutical partners seeking differentiated cancer therapy platforms.
NAYA Biosciences became publicly traded via a reverse merger with Invo Bioscience (Nasdaq: INVO) in October 2024, and was founded in 2023 with headquarters in Sarasota, Florida. The company has been actively building scale through M&A — most notably the $20 million acquisition of Florida Biotechnologies in H1 2024 — and through a European Research & Manufacturing Hub at the Paris-Saclay Cancer Cluster announced in January 2026. Capital sources include a $9.5 million public offering (January 2025) and a $4.0 million financing led by Maxim Group (December 2025), used to fund clinical development, asset acquisitions, and corporate purposes.
NAYA Biosciences firmographics
Firmographics- Name
- NAYA Biosciences
- Legal name
- NAYA Therapeutics
- Website
- https://nayabiosciences.com
- Company type
- Public
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- NAYA Biosciences is a publicly traded clinical-stage biopharmaceutical company developing Astatine-211 targeted alpha radiopharmaceuticals and FLEX-NK bifunctional antibodies for cancers refractory to standard-of-care, with an initial focus on hepatocellular carcinoma and multiple myeloma.
- Ownership category
- akta.pro rank
NAYA Biosciences industry classification
Industry- Product category
- Clinical-Stage Oncology Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB)
- akta.pro secondary industries
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx) (HLAIAGAC)
Keywords
Where NAYA Biosciences is headquartered
LocationHeadquarters
- HQ city
- Sarasota
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
NAYA Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Pharmaceutical Development and Licensing: As a clinical-stage biopharmaceutical company, NAYA Biosciences generates revenue through development milestones, licensing agreements, and potential commercialization of its cancer therapy pipelines. The company announced a $9.5 million public offering to fund clinical development and asset acquisitions.
- Public Offering: The company completed a $9.5 million public offering involving the sale of units including shares and warrants to fund clinical development, asset acquisitions, and other corporate purposes.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
NAYA Biosciences product offering
Product offeringCore offering
NAYA Biosciences is a clinical-stage biopharmaceutical company developing two proprietary oncology platforms: an Astatine-211 (At-211) targeted alpha radiopharmaceutical platform and a FLEX-NK bifunctional antibody platform that engages natural killer (NK) cells to attack tumors. Its lead programs target hepatocellular carcinoma (HCC) and multiple myeloma, with a current product candidate set including NYA-Ast-001, NYA-Ast-002, and NYA-NK-001. The company intends to commercialize via out-licensing, co-development partnerships, and direct sales upon regulatory approval.
Product overview
NAYA Therapeutics is a clinical-stage biopharmaceutical company developing a portfolio of cancer immunotherapies. The company operates two core technology platforms: Astatine-211 Targeted Alpha Therapies (radiopharmaceuticals using alpha emitter technology) and FLEX-NK Bifunctional Antibodies (NK-cell engaging antibodies). The company also acquired Florida Biotechnologies in 2024. Initial therapeutic focus areas are hepatocellular carcinoma (HCC) and multiple myeloma. NAYA also established a European Research & Manufacturing Hub at Paris-Saclay Cancer Cluster.
Differentiator
Problem solved
Functional benefit
Products and services
- NYA-Ast-001
- NYA-Ast-002
- NYA-NK-001
Companies that use NAYA Biosciences
Customer profileSegments2 records
Ideal customer profiles1 record
NAYA Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
NAYA Biosciences partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core.
- Atley SolutionscorePartnership announced January 7th, 2026 to accelerate development and commercialization of astatine-211 radiopharmaceuticals. Atley Solutions CEO Milton Lönnroth is building a supply chain for on-demand ²¹¹At availability.
- Paris-Saclay Cancer ClustercoreNAYA announced establishment of European Research & Manufacturing Hub at Paris-Saclay Cancer Cluster in January 2026 to expand manufacturing capabilities in Europe.
- Alpha NuclidecoreAlpha Nuclide provides astatine-211 supply for NAYA's radiopharmaceutical programs. CEO Yutian Feng, PhD, discusses the properties of astatine-211 and the company's role in global biotech supply chain development.
- Miami Cancer InstitutecoreDr. Manmeet Ahluwalia, Chief of Medical Oncology, Deputy Director, and Chief Scientific Officer at Miami Cancer Institute, discusses promise of astatine-211 in treating minimal residual disease.
Scale indicators3 records
Recent moves7 records
Expansion highlights5 records
NAYA Biosciences competitors and assessment
Company assessmentBroad incumbents
- Fate Therapeutics: Clinical-stage cell therapy company focused on iPSC-derived NK and T-cell immunotherapies; comparable in NK-cell biology and oncology focus, with a broader pipeline and larger capital base.
- Telix Pharmaceuticals: Commercial-stage radiopharmaceutical company with approved imaging agents and growing therapeutic pipeline; provides incumbent comparison for radiopharma commercialization and supply-chain scale that NAYA must eventually match.
- Lantheus Holdings: Established radiopharmaceutical company with commercial products (e.g., Pylarify) and growing alpha-therapy programs; relevant comparable for radiopharma manufacturing, regulatory, and commercial dynamics NAYA will face.
- ImmunityBio: Clinical-to-commercial stage immunotherapy company developing NK-cell engagers and cytokine-based therapies for solid tumors; comparable in NK-engager mechanism and oncology indications of interest to NAYA.
Direct peers
- Actinium Pharmaceuticals: Clinical-stage radiopharmaceutical company developing targeted alpha therapies using actinium-225 and iodine-131; closest direct peer to NAYA's ²¹¹At alpha-therapy platform, with overlapping indication focus in oncology.
- Perspective Therapeutics: Clinical-stage radiopharmaceutical company developing targeted alpha and beta therapies (²¹²Pb, ²⁰³Pb) for solid tumors; highly comparable to NAYA's emerging ²¹¹At radiopharma platform both in modality and stage.
- Innate Pharma: Clinical-stage immuno-oncology company pioneering NK-cell engagers and bispecific antibodies; directly comparable to NAYA's FLEX-NK bifunctional antibody platform targeting hard-to-treat cancers.
- MacroGenics: Clinical-stage biotech developing bispecific antibodies and antibody-based therapeutics for cancer, including NK-engaging formats; operates a similar bifunctional antibody discovery engine as NAYA's FLEX-NK.
Emerging players
- Nkarta: Clinical-stage biotech engineering NK-cell therapies and NK engagers for hematologic malignancies and solid tumors; comparable mechanism and indication set (multiple myeloma overlap) to FLEX-NK.
- GT Biopharma: Clinical-stage immuno-oncology company developing NK-cell engager (TriKE) bispecifics; directly comparable mechanism to FLEX-NK and similar small-cap clinical-stage profile.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights5 records
Customer concentration
NAYA Biosciences social profiles
Digital presenceNAYA Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
NAYA Biosciences leadership team
Management profileNumber of profiles
Profiles2 records
NAYA Biosciences subsidiaries and ownership
Company hierarchySubsidiaries1 record
NAYA Biosciences funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NAYA Biosciences M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NAYA Biosciences
What does NAYA Biosciences do?
NAYA Biosciences is a clinical-stage biopharmaceutical company developing two proprietary oncology platforms: an Astatine-211 (At-211) targeted alpha radiopharmaceutical platform and a FLEX-NK bifunctional antibody platform that engages natural killer (NK) cells to attack tumors. Its lead programs target hepatocellular carcinoma (HCC) and multiple myeloma, with a current product candidate set including NYA-Ast-001, NYA-Ast-002, and NYA-NK-001. The company intends to commercialize via out-licensing, co-development partnerships, and direct sales upon regulatory approval.
Is NAYA Biosciences a public or private company?
NAYA Biosciences is a public company. It is classified as public and is currently operating.
When was NAYA Biosciences founded?
NAYA Biosciences was founded in 2023. It employs 1 to 10 people.
Where is NAYA Biosciences based?
NAYA Biosciences is headquartered in Sarasota, United States, in the North America region.
How does NAYA Biosciences make money?
Two revenue lines are on record. Pharmaceutical Development and Licensing is the primary driver. The others are public Offering.
Who are NAYA Biosciences's main competitors?
Broad incumbents on record are Fate Therapeutics, Telix Pharmaceuticals, Lantheus Holdings and ImmunityBio. Direct peers are Actinium Pharmaceuticals, Perspective Therapeutics, Innate Pharma and MacroGenics. Emerging players are Nkarta and GT Biopharma.
Does NAYA Biosciences have an API?
No public API is recorded for NAYA Biosciences.
What industry is NAYA Biosciences in?
NAYA Biosciences's product category is Clinical-Stage Oncology Therapeutics. Its primary akta.pro industry code is HLAIAGAB, Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy), with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 325414 and its SIC code is 2834.